What Is Glucagon-Like Peptide-3?

Glucagon-like peptide-3 is a peptide fragment produced during the processing of proglucagon, a precursor protein encoded by the GCG gene. Proglucagon is expressed primarily in the alpha cells of the pancreas, the L-cells of the intestine, and certain neurons in the brainstem. When enzymes called prohormone convertases cleave proglucagon at different sites, they generate a family of related peptides. The best-known members of this family are glucagon, GLP-1, and GLP-2. GLP-3 is a smaller fragment that emerges from the same cleavage process, though its exact boundaries and biological significance are still being worked out.

The proglucagon gene encodes a protein of 180 amino acids. Tissue-specific processing determines which peptides get released. In the pancreas, the dominant products are glucagon and a fragment called glicentin-related pancreatic peptide. In the intestine and brain, the processing favors GLP-1, GLP-2, and oxyntomodulin. GLP-3 appears to be a byproduct of this intestinal processing, but it has not been isolated and characterized with the same rigor as GLP-1 or GLP-2. Some researchers have described it as a short intervening peptide sequence rather than a fully independent hormone.

Part of the reason GLP-3 remains obscure is that it is difficult to measure reliably in biological samples. GLP-1 and GLP-2 have well-validated assays and known receptors, which made studying them tractable. GLP-3 lacks a confirmed receptor, which means researchers have fewer tools to trace its activity in living systems. That gap in the toolkit has slowed progress considerably.

How Does GLP-3 Fit Into the Proglucagon Family?

To understand GLP-3's place in the literature, it helps to know the broader proglucagon map. The proglucagon protein contains several distinct peptide sequences arranged in a linear chain. After the signal peptide is removed, the mature proglucagon molecule includes glicentin-related pancreatic peptide, glucagon, oxyntomodulin, GLP-1, an intervening peptide, GLP-2, and a short C-terminal fragment. GLP-3 is sometimes used to refer to that intervening peptide region or to the C-terminal fragment, depending on the source. The naming has not been fully standardized across the literature, which adds to the confusion for readers encountering the term for the first time.

GLP-1 is the most studied member of the family by a wide margin. It stimulates insulin secretion in a glucose-dependent manner, slows gastric emptying, and acts on the brain to reduce appetite. Pharmaceutical versions of GLP-1 receptor agonists, including semaglutide (approved as Wegovy and Ozempic) and liraglutide (approved as Victoza and Saxenda), are FDA-approved drugs for type 2 diabetes and obesity management. Those approvals apply to the branded pharmaceutical products, not to research-chemical versions of GLP-1 peptides. GLP-2, meanwhile, has a well-characterized receptor and plays a documented role in intestinal growth and nutrient absorption. Teduglutide, a GLP-2 analogue, is FDA-approved as Gattex for short bowel syndrome.

GLP-3 sits in a different category entirely. It has no approved pharmaceutical form, no confirmed receptor, and no established physiological function. Researchers have not yet demonstrated that GLP-3 circulates at meaningful concentrations in human blood or that it binds to any specific cell-surface protein. That doesn't mean it has no function, but it does mean the field has not yet produced the evidence needed to say what that function might be.

What Does Early Research Suggest About GLP-3's Biology?

The available research on GLP-3 is sparse and largely preclinical. Some early biochemical work identified the GLP-3 sequence as part of the proglucagon processing products in intestinal L-cells, but those studies were primarily mapping the cleavage products rather than testing biological activity. A small number of in-vitro experiments have looked at whether GLP-3 fragments interact with known glucagon-family receptors, including the GLP-1 receptor and the glucagon receptor, but no strong binding affinity has been confirmed for any of these targets.

One area that has attracted modest interest is whether GLP-3 might have weak insulinotropic properties, meaning it could influence insulin release from pancreatic beta cells. This hypothesis was partly motivated by structural similarities between GLP-3 and other members of the glucagon peptide superfamily, which includes GLP-1, GIP (glucose-dependent insulinotropic polypeptide), and glucagon itself. All of these peptides share a common evolutionary ancestor and have overlapping structural features. However, any insulinotropic effect attributed to GLP-3 in early studies was small and has not been replicated in controlled human trials.

Animal studies have occasionally detected GLP-3-like immunoreactivity in intestinal tissue, but immunoreactivity assays can cross-react with related peptides, making it hard to attribute findings specifically to GLP-3. The evidence base as of the mid-2020s consists mainly of biochemical characterization studies and a handful of rodent experiments. No large-scale animal studies and no human clinical trials focused specifically on GLP-3 have been published in the major endocrinology or gastroenterology journals.

How Does GLP-3 Compare to GLP-1 and GLP-2?

The contrast in research depth is striking. GLP-1 has been studied in hundreds of randomized controlled trials involving tens of thousands of human participants. Its receptor is cloned, its signaling pathways are mapped, and its downstream effects on insulin secretion, gastric motility, and appetite are well documented. GLP-2 has a smaller but still substantial clinical literature, including trials that established its role in intestinal adaptation and led to the approval of teduglutide. GLP-3 has none of that infrastructure behind it.

One practical reason for this gap is commercial interest. GLP-1 and GLP-2 attracted pharmaceutical investment early because researchers could demonstrate clear, measurable effects in animal models that translated to humans. That evidence justified the cost of drug development. GLP-3 has not yet produced that kind of signal. Without a confirmed receptor to target, it's difficult to design a drug candidate or even a clean research probe.

Another difference is stability. GLP-1 is rapidly degraded in the bloodstream by the enzyme dipeptidyl peptidase-4 (DPP-4), which is why pharmaceutical developers had to engineer DPP-4-resistant analogues to make it therapeutically useful. GLP-3's metabolic stability has not been well characterized, partly because researchers haven't had a strong reason to study it. If future work identifies a receptor or a biological function, stability and half-life will become important questions to answer.

It's worth noting that the naming conventions across the proglucagon family can mislead readers into thinking GLP-3 is simply the next step after GLP-2 in a well-understood series. It isn't. The numbering reflects the order of peptide sequences in the proglucagon precursor, not a hierarchy of biological importance or research maturity.

Where Does GLP-3 Research Stand Today?

As of the mid-2020s, GLP-3 remains one of the least-characterized products of proglucagon processing. It does not appear in major clinical trial registries as a primary compound under investigation. A search of ClinicalTrials.gov returns no registered trials with GLP-3 as a primary intervention. The peptide appears in the scientific literature mainly as a footnote in broader reviews of proglucagon biology or as part of assay validation studies that need to account for cross-reactivity between related peptides.

The growing commercial and scientific interest in GLP-1 receptor agonists has indirectly increased attention on the entire proglucagon family. As researchers look for new targets to complement or improve on GLP-1-based therapies, some have begun revisiting the less-studied proglucagon fragments. GLP-3 could attract more focused investigation if someone identifies a receptor or demonstrates a clear physiological effect in a well-controlled model. Until that happens, it remains a biochemical curiosity rather than a research priority.

For readers who encounter GLP-3 mentioned in supplement marketing or on research-chemical vendor sites, it's worth knowing that no peer-reviewed evidence supports any specific health application for GLP-3 in humans. The compound has no approved use, no established safety profile in humans, and no clinical trial data to draw on. Any claims about its effects in people go well beyond what the current evidence record supports.

Frequently asked questions

Is GLP-3 the same thing as GLP-1 or GLP-2?

No. GLP-1, GLP-2, and GLP-3 are all derived from the same precursor protein, proglucagon, but they are distinct peptide sequences with different structures. GLP-1 has a well-characterized receptor and is the basis for several FDA-approved drugs. GLP-2 also has a confirmed receptor and an approved pharmaceutical analogue. GLP-3 has neither a confirmed receptor nor an established physiological role, and it is far less studied than either of its relatives.

Does GLP-3 have any FDA-approved uses?

No. GLP-3 has no FDA-approved pharmaceutical form and no approved medical use. This is different from GLP-1, where branded drugs like Ozempic, Wegovy, Victoza, and Saxenda carry FDA approval, and from GLP-2, where Gattex is approved for short bowel syndrome. Those approvals apply to specific branded products developed through clinical trials, not to the raw peptide sequences or any research-chemical versions.

Why is so little known about GLP-3 compared to GLP-1?

Several factors explain the gap. GLP-3 has no confirmed receptor, which makes it hard to study its activity in cells or living animals. Without a receptor, there's no obvious drug target, so pharmaceutical companies have had little incentive to fund large studies. GLP-1, by contrast, had a confirmed receptor early on, clear effects in animal models, and strong commercial interest that drove decades of clinical research. GLP-3 also lacks validated assays that can measure it precisely in blood or tissue without cross-reacting with related peptides, which makes even basic characterization work difficult.

Sources

  1. Drucker DJ, 2002, Journal of Clinical Investigation, Biological actions and therapeutic potential of the proglucagon-derived peptides Foundational review of proglucagon processing and peptide biology
  2. Holst JJ, 2007, Physiological Reviews, The physiology of glucagon-like peptide 1 Comprehensive GLP-1 review providing family context
  3. Brubaker PL & Drucker DJ, 2004, Endocrinology, Minireview: Glucagon-like peptides regulate cell proliferation and apoptosis in the pancreas, gut, and central nervous system Covers proglucagon-derived peptide functions including lesser-known fragments

Educational and informational content only. This is not medical advice, diagnosis, or treatment. The compounds discussed are research compounds that are not approved for human use outside specific prescribed contexts. Always consult a qualified, licensed clinician before making any health decision.